469 related articles for article (PubMed ID: 33802004)
1. Complement in Tumourigenesis and the Response to Cancer Therapy.
O'Brien RM; Cannon A; Reynolds JV; Lysaght J; Lynam-Lennon N
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33802004
[TBL] [Abstract][Full Text] [Related]
2. The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy.
Geller A; Yan J
Front Immunol; 2019; 10():1074. PubMed ID: 31164885
[TBL] [Abstract][Full Text] [Related]
3. Targeting innate immune pathways in cancer immunotherapy: state of the art.
Mastellos DC
J BUON; 2009 Sep; 14 Suppl 1():S123-30. PubMed ID: 19785054
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.
Kakavand H; Wilmott JS; Long GV; Scolyer RA
Pathology; 2016 Feb; 48(2):194-202. PubMed ID: 27020392
[TBL] [Abstract][Full Text] [Related]
5. Complement and Cancer-A Dysfunctional Relationship?
Thurman JM; Laskowski J; Nemenoff RA
Antibodies (Basel); 2020 Nov; 9(4):. PubMed ID: 33167384
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer.
Kleczko EK; Kwak JW; Schenk EL; Nemenoff RA
Front Immunol; 2019; 10():954. PubMed ID: 31134065
[TBL] [Abstract][Full Text] [Related]
7. Complement System: Promoter or Suppressor of Cancer Progression?
Revel M; Daugan MV; Sautés-Fridman C; Fridman WH; Roumenina LT
Antibodies (Basel); 2020 Oct; 9(4):. PubMed ID: 33113844
[TBL] [Abstract][Full Text] [Related]
8. The tumour microenvironment links complement system dysregulation and hypoxic signalling.
Olcina MM; Kim RK; Melemenidis S; Graves EE; Giaccia AJ
Br J Radiol; 2019 Jan; 92(1093):20180069. PubMed ID: 29544344
[TBL] [Abstract][Full Text] [Related]
9. Complement Inhibition: A Novel Form of Immunotherapy for Colon Cancer.
Downs-Canner S; Magge D; Ravindranathan R; O'Malley ME; Francis L; Liu Z; Sheng Guo Z; Obermajer N; Bartlett DL
Ann Surg Oncol; 2016 Feb; 23(2):655-62. PubMed ID: 26289805
[TBL] [Abstract][Full Text] [Related]
10. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
11. Complement system's role in cancer and its therapeutic potential in ovarian cancer.
Bareke H; Akbuga J
Scand J Immunol; 2018 Jul; 88(1):e12672. PubMed ID: 29734524
[TBL] [Abstract][Full Text] [Related]
12. The Complement System: A Potential Therapeutic Target in Liver Cancer.
Yuan M; Liu L; Wang C; Zhang Y; Zhang J
Life (Basel); 2022 Sep; 12(10):. PubMed ID: 36294966
[TBL] [Abstract][Full Text] [Related]
13. Complement as a Biological Tool to Control Tumor Growth.
Macor P; Capolla S; Tedesco F
Front Immunol; 2018; 9():2203. PubMed ID: 30319647
[TBL] [Abstract][Full Text] [Related]
14. Mesenchymal stromal cells (MSCs) and colorectal cancer: a troublesome twosome for the anti-tumour immune response?
O'Malley G; Heijltjes M; Houston AM; Rani S; Ritter T; Egan LJ; Ryan AE
Oncotarget; 2016 Sep; 7(37):60752-60774. PubMed ID: 27542276
[TBL] [Abstract][Full Text] [Related]
15. Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy.
Ginefra P; Lorusso G; Vannini N
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580431
[TBL] [Abstract][Full Text] [Related]
16. Complement links platelets to innate immunity.
Nording H; Langer HF
Semin Immunol; 2018 Jun; 37():43-52. PubMed ID: 29426568
[TBL] [Abstract][Full Text] [Related]
17. Complement anaphylatoxins C3a and C5a: Emerging roles in cancer progression and treatment.
Ajona D; Ortiz-Espinosa S; Pio R
Semin Cell Dev Biol; 2019 Jan; 85():153-163. PubMed ID: 29155219
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.
Hartl CA; Bertschi A; Puerto RB; Andresen C; Cheney EM; Mittendorf EA; Guerriero JL; Goldberg MS
J Immunother Cancer; 2019 Jul; 7(1):199. PubMed ID: 31362778
[TBL] [Abstract][Full Text] [Related]
19. Innate and Adaptive Immune Cell Metabolism in Tumor Microenvironment.
Wu D
Adv Exp Med Biol; 2017; 1011():211-223. PubMed ID: 28875492
[TBL] [Abstract][Full Text] [Related]
20. Local tumour hyperthermia as immunotherapy for metastatic cancer.
Toraya-Brown S; Fiering S
Int J Hyperthermia; 2014 Dec; 30(8):531-9. PubMed ID: 25430985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
